Significant, ( & sadly due to Covid 19) and likely a rapidly growing need for an effective product
Product Safety phase 1 Trials already in progress with some disease patients likely to be also included in those trials in early 2021
to date no toxicity issues presented so far in animal studies or in the human trials.
The product (AD214) appears to have (compared to alternatives) high specificity, tollerance, safety, and all indications also suggest efficacy (effective against the target disease)
Platform technology ( a wide range of other future disease targets and "other" uses could likely come from this technology )
Partnerships ( and already an income from one of those "other" uses of the product from GE Healthcare)
most importantly this drug will hopefully make a big difference to the length and quality of life for a lot of IPF patients and their families
all the best to all the other long term holders fp
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)